Evaluation of safety and efficacy to abatacept treatment of patients with HBV-related acute liver failure.-Pilot Study-

Evaluation of safety and efficacy to abatacept treatment of patients with HBV-related acute liver failure.-Pilot Study- - A pilot study of abatacept treatment in actu HBV patients with liver failure.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016148

Enrollment

Registered

2015-01-07

Start date

2015-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV-related acute liver failure

Interventions

To evaluate safety and efficacy to abatacept treatment of patients with HBV-related acute liver failure.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HBs antigen positive Less than PT 40%

Exclusion criteria

Exclusion criteria: 1) Autoimmune hepatitis 2) History of hypersensitivity to abatacept 3) Hepatic coma 4) HBV carrier 5) Serious infectious disease 6) Judged by investigator not to be appropriate for inclusion in this study

Design outcomes

Primary

Measure	Time frame
Ratio of patient with liver failur improved one week after treatment (Ratio of patient that PT was restored than 50%)	—

Secondary

Measure	Time frame
Period of ALT being normalized Safety (moniterd clinical and laboratory evaluation)	—

Countries

Japan

Contacts

Public ContactYoshiiku Kawakami

graduate school of biomedical science, Hiroshima university Department and medicine and molecular science

kamy4419@hiroshima-u.ac.jp082-257-5190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026